{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-291992","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.694037+00:00","generated_at":"2026-05-16T17:21:15.372773+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Invivyd selects RSV antibody candidate VBY329; 2H 2026 IND readiness targeted","bullets":["VBY329 showed 1.5x greater potency vs nirsevimab, 1.2x vs clesrovimab against authentic RSV strains.","Up to ~500-fold enhanced neutralization vs nirsevimab-resistant variants in pseudovirus assays.","Half-life extension technology expected to expand protective window vs standard of care.","Pediatric RSV prophylaxis market estimated $3-4B annually globally by 2030.","Additional discovery efforts for ultra-long half-life RSV antibodies for elderly/immunocompromised."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-291992","json":"https://secwatch.observer/filing/0001193125-25-291992.json","markdown":"https://secwatch.observer/filing/0001193125-25-291992.md","text":"https://secwatch.observer/filing/0001193125-25-291992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312525291992/0001193125-25-291992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312525291992/ivvd-20251124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:21:15.372773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}